Clinical Trial Update: A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating CMX001 for prevention of CMV infection in CMV-seropositive hematopoietic cell transplantation recipients has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• CMX001 (brincidofovir)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: CMV | Phase 3 | Status: COMPLETED | Results posted: 2021-01-05